A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTO
Trial details
- Registry ID
- NCT07734844
- Drugs studied
- Aflibercept (2.0 mg), Tabirafusp tedromer
TrialRedline tracks 11 clinical trials sponsored by Kodiak Sciences Inc: 10 Phase 3, 1 Phase 2 / 3.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration.NCT04049266 | Aflibercept, KSI-301, Sham Procedure | Terminated | 2021-11-17Actual |
Names as written in the registry records.
Before: Estimated. After: Actual.
Before: 675 participants (planned). After: 667 participants (actual).
Before: Estimated. After: Actual.
Before: Aug 2026. After: 2 Sep 2026.
Before: 150 participants (planned). After: 300 participants (planned).
Before: Dec 2026. After: Feb 2027.
Before: 150 participants (planned). After: 600 participants (planned).
Before: Feb 2026. After: Apr 2027.
Before: Estimated. After: Actual.
Before: 31 Jan 2026. After: 13 Feb 2026.
Before: Active not recruiting. After: Completed.